Clinical trials: Tumor Pancreas
Anal Cancer, Carcinoma of the Appendix
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00903396
- Testing
- palonosetron hydrochloride
- Where
- 69 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Cancer
Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer
To determine the response rate and survival of gemcitabine and pazopanib in patients with metastatic pancreatic cancer.
- Trial name
- NCT01080248
- Testing
- Gemcitabine, Pazopanib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Washington University School of Medicine
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Radiation Therapy, SBRT
SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy
Thisi is an Interventional drug-free randomized 1:1 open-label, multicenter, phase 3 trial in patients with first-line metastatic pancreatic cancer.
- Conditions
- Radiation Therapy, SBRT, Pancreatic Cancer Metastatic
- Trial name
- SENECA (NCT06946420)
- Testing
- SBRT or RT on primary pancreatic and/or metastatic distant lesions before chemotherapy, Standard systemic therapy (chemotherapy) without RT/SBRT
- Where
- Italy
- Volunteers
- 108 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Pancreatic Neoplasms
Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery
The purpose of this study is to find out if a program of intensive chemotherapy with gemcitabine, docetaxel and capecitabine followed by an advanced form of focused radiation aimed at the patient's tumor followed by more…
- Trial name
- NCT00833859
- Testing
- GTX (gemcitabine, docetaxel and capecitabine), stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-small Cell Lung Cancer, Pancreatic Cancer
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.
- Conditions
- Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Loss of Appetite
- Trial name
- PROACC-1 (NCT05546476)
- Testing
- ponsegromab
- Where
- 78 sites in United States, Australia and 9 more
- Volunteers
- 187 people
- Sponsor
- Pfizer
Obstructive Jaundice, Pancreatic Cancer
Trial Comparing Metal Versus Plastic Stents for Preoperative Biliary Decompression
Compare the performance of full covered metal stents and plastic stents for preoperative biliary decompression
- Trial name
- NCT01675908
- Testing
- Stent Dysfunction, Complications
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- AdventHealth
Diamond Blackfan Anemia, Dyskeratosis Congenita
Cancer in Inherited Bone Marrow Failure Syndromes
Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders.
- Conditions
- Diamond Blackfan Anemia, Dyskeratosis Congenita, Fanconi Anemia, Shwachman Diamond Syndrome
- Trial name
- NCT00027274
- Where
- 2 sites in United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Neoplasm, Pancreatic Diseases
RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses
Background: EUS-guided fine needle aspiration (EUSFNA) is a well established technique for tissue acquisition and diagnosis with excellent safety profile.
- Trial name
- NCT02092519
- Testing
- Needle with sideport (NA-230H-8020), Needle without sideport (NA-220H-8022)
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Changi General Hospital
Breast Cancer, Lung Cancer
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.
- Conditions
- Breast Cancer, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer
- Trial name
- NCT02947165
- Testing
- NIS793, PDR001
- Where
- 12 sites in United States, Austria and 7 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor, Adult, Advanced Solid Tumor
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer
- Trial name
- NCT05864144
- Testing
- SNS-101 (anti-VISTA), Cemiplimab
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sensei Biotherapeutics, Inc.
Pancreatic Cancer Non-resectable
Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
This study is a prospective, single-arm trial, aiming to enroll 30 patients with unresectable locally advanced or oligometastatic pancreatic cancer.
- Trial name
- NCT07386704
- Testing
- Nimotuzumab combined with chemoradiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Pancreatic Cancer
Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer
The purpose of this study is to evaluate the impact of the addition of cisplatin to gemcitabine in the treatment of patients with inoperable advanced pancreatic cancer.
- Trial name
- GIP-1 (NCT00813696)
- Testing
- gemcitabine, cisplatin
- Where
- 45 sites in Italy
- Volunteers
- 400 people
- Sponsor
- Istituti Tumori Giovanni Paolo II
Pancreatic Cancer
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
This study is a multicenter, open-label, single-arm, phase Ib/II clinical study comprising two phases: dose confirmation phase and dose expansion phase.
- Trial name
- NCT05827796
- Testing
- IN10018, Albumin-Bound Paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 70 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Advanced Solid Tumor, Breast Cancer
A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer
The study will evaluate the pharmacokinetics (PK) and safety of a single intravenous (IV) dose of 0.3 mg/kg MB1707 in patients with advanced cancers.
- Conditions
- Advanced Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer, Ovary Cancer
- Trial name
- NCT05465590
- Testing
- MB1707
- Sponsor
- Mainline Biosciences, Inc.
Pancreatic Ductal Adenocarcinoma
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
The goal of this clinical study is to compare the efficacy and safety of OT-101 in combination with mFOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to mFOLFIRINOX alone in patients with advanced and unresectable or…
- Trial name
- STOP-PC (NCT06079346)
- Testing
- OT-101, mFOLFIRINOX
- Where
- 2 sites in United States
- Volunteers
- 455 people
- Sponsor
- Oncotelic Inc.
Pancreatic Cancer
Identify the Clinical Significance and Potential Implications of Peritoneal Washing Cytology (PWC) in Patients With Pancreatic Cancer
Pancreatic cancer is a disease with an extremely poor prognosis. Such poor results are largely due to a high incidence of local or peritoneal recurrence even after curative R0 resection.
- Trial name
- NCT01127815
- Volunteers
- 300 people
- Sponsor
- National Taiwan University Hospital
Pancreatic Cancer
Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer
The goal of this clinical research study is to find the highest safe dose of the drug Bevacizumab that can be given in combination with chemoradiation for the treatment of pancreatic cancer.
- Trial name
- NCT00047710
- Testing
- Bevacizumab, Capecitabine, Radiotherapy
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Chronic Liver Disease, Thyroid Disease
The Development of Quantitative Ultrasound Imaging Software Platform
The goal of this observational study is to compare the image differences between conventional ultrasound and artificial intelligence-based ultrasound software in conscious adults.
- Conditions
- Chronic Liver Disease, Thyroid Disease, Benign Breast Disease, Malignant Breast Neoplasm
- Trial name
- NCT05836246
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Seoul National University Bundang Hospital
Gastrointestinal Cancer, Colon Cancer
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
This research study is being conducted to improve the quality of care of participants who have a diagnosis of gastrointestinal cancer (anal, colon, rectal, esophageal, stomach, small bowel, appendix, pancreas, gall bladder…
- Conditions
- Gastrointestinal Cancer, Colon Cancer, Rectal Cancer, Anal Cancer
- Trial name
- NCT06263088
- Testing
- EQUITY GI
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Case Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.